130 related articles for article (PubMed ID: 2697597)
21. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging.
Lecouvet FE; Vande Berg BC; Michaux L; Malghem J; Maldague BE; Jamart J; Ferrant A; Michaux JL
Radiology; 1998 Dec; 209(3):653-60. PubMed ID: 9844655
[TBL] [Abstract][Full Text] [Related]
22. Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma: a histopathological evaluation of biopsies from 153 untreated patients.
Sailer M; Vykoupil KF; Peest D; Coldewey R; Deicher H; Georgii A
Eur J Haematol; 1995 Mar; 54(3):137-46. PubMed ID: 7720832
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma: prognostic factors and treatment modalities.
Michiels JJ
Neth J Med; 1992 Jun; 40(5-6):254-70. PubMed ID: 1436263
[No Abstract] [Full Text] [Related]
24. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.
Witzig TE; Gertz MA; Lust JA; Kyle RA; O'Fallon WM; Greipp PR
Blood; 1996 Sep; 88(5):1780-7. PubMed ID: 8781435
[TBL] [Abstract][Full Text] [Related]
26. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
27. Beta 2 microglobulin in multiple myeloma.
Alexanian R; Barlogie B; Fritsche H
Am J Hematol; 1985 Dec; 20(4):345-51. PubMed ID: 3907332
[TBL] [Abstract][Full Text] [Related]
28. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
Kraj M; Maj S; Pogłód R; Rostkowska J
Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
[TBL] [Abstract][Full Text] [Related]
29. Lymphoproliferative disorders in the bone marrow: histologic criteria for classification and staging.
Bartl R; Frisch B; Hoffmann-Fezer G; Burkhardt R
Haematologia (Budap); 1984; 17(2):227-46. PubMed ID: 6534830
[TBL] [Abstract][Full Text] [Related]
30. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
32. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
[TBL] [Abstract][Full Text] [Related]
33. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
34. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
35. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
36. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
38. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial.
Brown RD; Joshua DE; Nelson M; Gibson J; Dunn J; MacLennan IC
Br J Haematol; 1993 Jun; 84(2):238-41. PubMed ID: 8398824
[TBL] [Abstract][Full Text] [Related]
39. Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma.
Avilés A; Zepeda G; Díaz-Maqueo JC; Rodriguez L; Guzmán R; García EL; Talavera A
Leuk Lymphoma; 1992 May; 7(1-2):135-8. PubMed ID: 1472924
[TBL] [Abstract][Full Text] [Related]
40. Histomorphology of multiple myeloma on bone marrow biopsy.
Singhal N; Singh T; Singh ZN; Shome DK; Gaiha M
Indian J Pathol Microbiol; 2004 Jul; 47(3):359-63. PubMed ID: 16295424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
